Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

被引：0

作者：

Laurie E. McLouth

Yue Zheng

Stephanie Smith

F. Stephen Hodi

Uma N. Rao

Gary I. Cohen

Thomas T. Amatruda

Shaker R. Dakhil

Brendan D. Curti

Ibrahim Nakhoul

Sreenivasa R. Chandana

Charles L. Bane

David E. Marinier

Sandra J. Lee

Vernon K. Sondak

John M. Kirkwood

Ahmad A. Tarhini

Lynne I. Wagner

机构：

[1] University of Kentucky,Department of Behavioral Science, College of Medicine, Markey Cancer Center

[2] Dana-Farber Cancer Institute—ECOG-ACRIN Biostatistics Center,Nancy N. and J.C. Lewis Cancer and Research Pavilion

[3] St. Joseph’s/Candler,undefined

[4] Dana-Farber Cancer Institute/Harvard Cancer Center,undefined

[5] University of Pittsburgh Cancer Institute,undefined

[6] Greater Baltimore Medical Center,undefined

[7] Minnesota Oncology,undefined

[8] Ascension Via Christi Hospitals,undefined

[9] Earle A. Chiles Research Institute,undefined

[10] Providence Cancer Institute,undefined

[11] Regional Cancer Center at Indian Path Community Hospital,undefined

[12] Cancer and Hematology Centers of Western Michigan/Cancer Research Consortium of West Michigan NCORP,undefined

[13] Good Samaritan Hospital-Dayton,undefined

[14] Gundersen Health System,undefined

[15] Moffitt Cancer Center,undefined

[16] Atrium Health Wake Forest Baptist Comprehensive Cancer Center,undefined

来源：

Quality of Life Research | 2023年 / 32卷

关键词：

Ipilimumab; Melanoma; Adjuvant therapy; Interferon; Patient-reported outcomes; Quality of life;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：183 / 196

页数：13

共 50 条

[31] Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.
Lian, Bin
Cui, Chuanliang
Si, Lu
Yang, Yue
Wu, Di
Li, Ke
Wang, Xuan
Chi, Zhihong
Sheng, Xinan
Mao, Lili
Tang, Bixia
Yan, Xieqiao
Li, Siming
Bai, Xue
Zhou, Li
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Hansson, Johan
Aamdal, Steinar
Bastholt, Lars
Brandberg, Yvonne
Hernberg, Micaela
Nilsson, Bo
Stierner, Ulrika
von der Maase, Hans
LANCET ONCOLOGY, 2011, 12 (02): : 144 - 152
[33] Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Brandberg, Y.
Aamdal, S.
Bastholt, L.
Hernberg, M.
Stierner, U.
von der Maase, H.
Hansson, J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 2012 - 2019
[34] E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Tarhini, Ahmad A.
Lee, Sandra J.
Li, Xiaoxue
Rao, Uma N. M.
Nagarajan, Arun
Albertini, Mark R.
Mitchell, Jerry W., Jr.
Wong, Stuart J.
Taylor, Mark A.
Laud, Noel
Truong, Phu, V
Conry, Robert M.
Kirkwood, John M.
CLINICAL CANCER RESEARCH, 2019, 25 (02) : 524 - 532
[35] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Hoos, Axel
de Pril, Veerle
Gurunath, Ravichandra Karra
de Schaetzen, Gaetan
Suciu, Stefan
Testori, Alessandro
LANCET ONCOLOGY, 2015, 16 (05): : 522 - 530
[36] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Bottomley, Andrew
Coens, Corneel
Suciu, Stefan
Santinami, Mario
Kruit, Willem
Testori, Alessandro
Marsden, Jeremy
Punt, Cornelis
Sales, Francois
Gore, Martin
MacKie, Rona
Kusic, Zvonko
Dummer, Reinhard
Patel, Poulam
Schadendorf, Dirk
Spatz, Alain
Keilholz, Ulrich
Eggermont, Alexander
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2916 - 2923
[37] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
Mao, Lili
Si, Lu
Chi, Zhihong
Cui, Chuanliang
Sheng, Xinan
Li, Siming
Tang, Bixia
Guo, Jun
EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
[38] A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
Kaufman, Howard
Wang, Jiafeng
Curti, Brendan D.
Clark, Joseph
Ernstoff, Marc S.
Silk, Ann
Mehnert, Janice M.
Zloza, Andrew
Shih, Joe
McDermott, David F.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[39] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
Vanna Chiarion-Sileni
Paola Del Bianco
Antonella Romanini
Michele Guida
Adriano Paccagnella
Maurizio Dalla Palma
Emanuele Naglieri
Ruggero Ridolfi
Barbara Silvestri
Maria Michiara
Gian Luca De Salvo
BMC Cancer, 6
[40] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]
Chiarion-Sileni, V
Del Bianco, P
Romanini, A
Guida, M
Paccagnella, A
Dalla Palma, M
Naglieri, E
Ridolfi, R
Silvestri, B
Michiara, M
De Salvo, GL
BMC CANCER, 2006, 6 (1)

← 1 2 3 4 5 →